AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
BusulfanMelphalanAntineoplastic Agents, AlkylatingTransplantation ConditioningChemotherapy, Cancer, Regional PerfusionMyeloablative AgonistsTransplantation, AutologousMultiple MyelomaCyclophosphamideBone Marrow TransplantationAlkylating AgentsTransplantation, HomologousVidarabineWhole-Body IrradiationHepatic Veno-Occlusive DiseaseAntineoplastic Combined Chemotherapy ProtocolsThiotepaCombined Modality TherapyGraft vs Host DiseaseCarmustineGraft SurvivalImmunosuppressive AgentsHematologic NeoplasmsAmyloidosisHematopoietic Stem Cell TransplantationStem Cell TransplantationDisease-Free SurvivalTreatment OutcomeDose-Response Relationship, DrugSurvival AnalysisPrednisoneTransplantation ChimeraEtoposidePeripheral Blood Stem Cell TransplantationDrug EvaluationMisonidazoleThalidomideButhionine SulfoximineMyelodysplastic SyndromesMethionine SulfoximineLeukemiaAntineoplastic AgentsSurvival RateDrug ResistanceLeukemia, Myeloid, AcuteBoronic AcidsVincristineDrug MonitoringGlutathione TransferaseDrug Administration SchedulePyrazinesAntilymphocyte SerumLeukemia, MyeloidSulfonic AcidsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSpermatogoniaBone Marrow PurgingMetabolic Clearance RateHistocompatibilityOogoniaChlorambucilCytarabineAdministration, OralTime FactorsActuarial AnalysisBone MarrowPharmaceutical SolutionsFollow-Up StudiesExtremitiesHematologic DiseasesArea Under CurveBlood Cell CountDrug Synergism
CyclophosphamideCarboplatinFludarabineEtoposideCytoxanRegimenIntravenous busulfanDosesInduction chemotherapyHematopoietic Cell TransplantationStemDoseAlkylating agentsCancerTherapyDrugSideGemcitabineCarmustineMultiple myelomaFludarabine with melphalanRegimensIntravenousAlkeranThiotepaTransplantationNeuroblastomaClofarabineChemotherapyMyelomaAcutePatientsDecreaseTreatmentSevereCombinationTotalList
Cyclophosphamide5
Carboplatin2
  • Resource utilization and toxicities after carboplatin/etoposide/melphalan and busulfan/melphalan for autologous stem cell rescue in high-risk neuroblastoma using a national administrative database. (chop.edu)
  • I have also served as an associate medical director for the hospital which is where, along with our academic partners the Institute of Cancer Research (ICR), the carcinogens in cigarette smoke were discovered and many chemotherapeutic agents developed (including Busulfan, Melphalan, Chlorambucil, Carboplatin, and Abirotanone). (igcs.org)
Fludarabine7
  • Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and " by Betül Oran, Kwang Woo Ahn et al. (henryford.com)
  • We aimed to compare the two most commonly used RIC regimens, intravenous use of fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in myelodysplastic syndrome (MDS). (henryford.com)
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies. (uchicago.edu)
  • Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. (uchicago.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
Etoposide1
Cytoxan2
Regimen1
  • CIBMTR's definition of RIC was used: a regimen that incorporated an intravenous busulfan total dose ≤ 7.2 mg/kg, or a low-dose melphalan total dose of ≤ 150 mg/m(2). (henryford.com)
Intravenous busulfan2
  • Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. (stembook.org)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
Doses1
Induction chemotherapy2
  • Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. (uc.edu)
  • 3.2 mg/kg/day busulfan on days -5 to -3 and 140 mg/m 2 /day melphalan on day -2) in patients with multiple myeloma (MM) following bortezomib-based induction chemotherapy. (elsevierpure.com)
Hematopoietic Cell Transplantation1
  • Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation. (uchicago.edu)
Stem2
Dose2
  • Your doctor may need to change your dose or tell you to stop taking busulfan for a period of time to allow your blood count to return to normal if it has dropped too low. (medlineplus.gov)
  • Your doctor may adjust your dose of busulfan depending on your response to treatment and any side effects that you experience. (medlineplus.gov)
Alkylating agents2
Cancer5
  • Busulfan tablets are also used in combination with other drugs to destroy the bone marrow and cancer cells in preparation for a bone marrow transplant. (medlineplus.gov)
  • Also tell your doctor if you have taken busulfan before, but your cancer did not respond to the medication. (medlineplus.gov)
  • Melflufen is rapidly taken up by myeloma cells and is immediately split to deliver the entrapped melphalan, killing the cancer cell. (healthtree.org)
  • RÉSUMÉ Afin d'atteindre les objectifs de santé fixés par le pays pour 2011-2016, une analyse qualitative de l'exposition aux facteurs de risque de cancer au Qatar a été conduite en 2013. (who.int)
  • Les risques de cancer les plus élevés pour les Qatariens proviendraient de facteurs associés aux modes de vie, en particulier l'obésité, la sédentarité et le tabagisme. (who.int)
Therapy1
Drug1
  • Your doctor will order laboratory tests before, during and after your treatment to check your body's response to busulfan to see if your blood cells are affected by this drug. (medlineplus.gov)
Side1
  • If you take busulfan with other medications that may cause a low blood count, the side effects of the medications may be more severe. (medlineplus.gov)
Gemcitabine3
Carmustine1
Multiple myeloma4
Fludarabine with melphalan2
  • We aimed to compare the 2 most commonly used RIC regimens, i.v. fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in patients with myelodysplastic syndrome (MDS). (houstonmethodist.org)
  • RIC regimens consisted of fludarabine with melphalan +/- anti-thymocyte globulin (ATG) or fludarabine with cyclophosphamide with total-body irradiation in doses less than 500 cGy. (bvsalud.org)
Regimens2
  • Newly diagnosed myeloma patients who are eligible for ASCT are being treated with standard novel- agent induction regimens containing bortezomib ( Velcade , Millennium Pharmaceuticals, Inc). They are then given a combination of busulfan and melphalan as the pretransplant conditioning regimen, followed by lenalidomide ( Revlimid , Celgene Corporation) maintenance therapy until disease progression after ASCT. (medscape.com)
  • Subjects received total body irradiation/cyclophosphamide (n = 27) or busulfan/melphalan (n = 7) conditioning regimens. (emmes.com)
Intravenous3
  • Treatment consisted of busulfan 16 mg/kg, orally over 4 days (from days -5 to -2) in 6 hourly divided doses, and melphalan at a dose of 140 mg/m2 given by intravenous infusion over 5 min on day -1. (nih.gov)
  • Controlled trials comparing intravenous (IV) to oral melphalan have shown more myelosuppression with the IV formulation. (medicine.com)
  • Intravenous melphalan is available in different formulations. (medicine.com)
Alkeran1
Thiotepa1
  • Hormone problems are most often seen in persons who were treated with radiation to the brain, neck or pelvic area and those who received high doses of a class of chemotherapy drugs called alkylation agents (such as cyclophosphamide, busulfan, melphalan, thiotepa). (pogo.ca)
Transplantation2
  • We conducted a prospective pilot study to assess the feasibility and safety of high-dose busulfan/melphalan as conditioning therapy prior to autologous PBPC transplantation in pediatric patients with high-risk solid tumors. (nih.gov)
  • Consolidation therapy for newly diagnosed pediatric patients with high-risk neuroblastoma using busulfan/melphalan, autologous hematopoietic cell transplantation, ant_GD2 antibody, granulocyte-macrophage colony-stimulating factor, interleukin-2, and haploidentical Natural Killer Cells. (stjude.org)
Neuroblastoma1
  • So the new standard treatment for myeloablation in children with nasty, aggressive neuroblastoma should be melphalan plus busulfan. (ecancer.org)
Clofarabine1
  • 15. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. (nih.gov)
Chemotherapy1
  • RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and melphalan, before a donor peripheral stem cell transplant or bone marrow transplant helps stop the growth of cancer or abnormal cells. (bioseek.eu)
Myeloma1
  • Busulfan/melphalan conditioning treatment followed by lenalidomide maintenance is well tolerated, with no deaths to date," reported lead author Donna Reece, MD, director of the program for myeloma and related disorders at the Princess Margaret Hospital, Toronto, Canada, at a poster session during the workshop. (medscape.com)
Acute1
  • 9. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. (nih.gov)
Patients2
  • Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation of melphalan. (medicine.com)
  • Patients also receive busulfan IV over 2 hours every 6 hours on days -4 and -3 or melphalan IV over 2 hours on day -3. (bioseek.eu)
Decrease3
  • Busulfan can cause a severe decrease in the number of blood cells in your bone marrow. (medlineplus.gov)
  • A decrease in estimated creatinine clearance from 100 mL/minute to 30 mL/minute results in 28.2% reduction in clearance for a person with an ideal body weight (IBW) of 70 kg receiving IV melphalan. (medicine.com)
  • Body weight: A patient with an IBW of 45 kg receiving IV melphalan has a 28% decrease in clearance relative to a patient with IBW of 70 kg, while a patient with an IBW of 100 kg has a 31% increase in clearance as compared to a patient with an IBW of 70 kg. (medicine.com)
Treatment2
  • Your doctor will order laboratory tests before, during and after your treatment to check your body's response to busulfan to see if your blood cells are affected by this drug. (medlineplus.gov)
  • Discontinue treatment with melphalan for serious hypersensitivity reactions. (medicine.com)
Severe1
  • If you take busulfan with other medications that may cause a low blood count, the side effects of the medications may be more severe. (medlineplus.gov)
Combination1
Total1
List1
  • Many other medications may also interact with busulfan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)